Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel J Glazar

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
CPT: Pharmacometrics & Systems Pharmacology|December 31, 2024
A sample size analysis of a mathematical model of longitudinal tumor volume and progression-free survival for Bayesian individual dynamic predictions in recurrent high-grade gliomaDaniel J Glazar, Solmaz Sahebjam, Hsiang-Husan M Yu, et al.
Oral Oncology|March 6, 2022
Early response dynamics predict treatment failure in patients with recurrent and/or metastatic head and neck squamous cell carcinoma treated with cetuximab and nivolumabDaniel J Glazar, Matthew Johnson, Joaquim Farinhas, et al.
Journal of Applied Clinical Medical Physics|May 31, 2019
Re: Simulation analysis for tumor radiotherapy based on three-component mathematical modelsMeghan C Ferrall-Fairbanks, Daniel J Glazar, Renee J Brady, et al.
Journal of Clinical Medicine|July 2, 2020
Tumor Volume Dynamics as an Early Biomarker for Patient-Specific Evolution of Resistance and Progression in Recurrent High-Grade GliomaDaniel J Glazar, G Daniel Grass, John A Arrington, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
CPT: Pharmacometrics & Systems Pharmacology|December 31, 2024
A sample size analysis of a mathematical model of longitudinal tumor volume and progression-free survival for Bayesian individual dynamic predictions in recurrent high-grade gliomaDaniel J Glazar, Solmaz Sahebjam, Hsiang-Husan M Yu, et al.
Oral Oncology|March 6, 2022
Early response dynamics predict treatment failure in patients with recurrent and/or metastatic head and neck squamous cell carcinoma treated with cetuximab and nivolumabDaniel J Glazar, Matthew Johnson, Joaquim Farinhas, et al.
Journal of Applied Clinical Medical Physics|May 31, 2019
Re: Simulation analysis for tumor radiotherapy based on three-component mathematical modelsMeghan C Ferrall-Fairbanks, Daniel J Glazar, Renee J Brady, et al.
Journal of Clinical Medicine|July 2, 2020
Tumor Volume Dynamics as an Early Biomarker for Patient-Specific Evolution of Resistance and Progression in Recurrent High-Grade GliomaDaniel J Glazar, G Daniel Grass, John A Arrington, et al.
Pageof 1